Fabiani & Company partnered with an antibiotics company and waged a successful lobbying campaign for a legislative market exclusivity extension. As a result of that work, Congress passed S. 3560 in 2007, an amendment to the Food, Drug and Cosmetics Act, which allows our client to be eligible for five year market exclusivity under specified circumstances. Preliminary projections estimate the yearly sales for our client will be in the 100’s of millions of dollars for this one product.

Fabiani & Company secured funding of $3 million through the National Aeronautics and Space Administration (NASA) and the Centers for Disease Control and Prevention (CDC) for development of delivery devices for regenerative medicine, as well as over $3 million in additional funding through the Department of Energy for cardiovascular catheterization research. Fabiani & Company also successfully represented this company’s policy and legislative interests with respect to government payments for certain medical imaging procedures.

Fabiani & Company developed a legislative and federal agency advocacy strategy to help expedite a $30 million procurement contract for delivery to the U.S. Strategic National Stockpile.

Fabiani & Company helped the company secure more than $3 million in government funding to support collaborative research with the U.S. Army.

Fabiani & Company worked with a molecular diagnostics company to identify strategic federal collaborators and successfully win $1.6 million in Department of Defense (DOD) funding for a clinical assay validation study of military relevance.

Fabiani & Company helped this company secure a $28 million product development contract through the National Institute of Allergy and Infectious Diseases (NIAID).

Fabiani & Company helped this small device company secure a $7 million product development contract through the Defense Advanced Research Projects Agency (DARPA).